Tourmaline Bio (NASDAQ:TRML - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Tourmaline Bio to post earnings of ($0.91) per share for the quarter.
Shares of NASDAQ TRML traded up $1.37 on Tuesday, hitting $16.02. The company's stock had a trading volume of 387,563 shares, compared to its average volume of 283,023. The stock has a 50 day moving average of $15.91 and a 200-day moving average of $20.87. The company has a market capitalization of $410.80 million, a price-to-earnings ratio of -5.68 and a beta of 2.35. Tourmaline Bio has a 12-month low of $11.87 and a 12-month high of $48.31.
TRML has been the topic of a number of analyst reports. Wedbush initiated coverage on Tourmaline Bio in a research note on Thursday, March 6th. They set an "outperform" rating and a $42.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $49.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th. BMO Capital Markets initiated coverage on shares of Tourmaline Bio in a research note on Friday, December 6th. They set an "outperform" rating and a $50.00 price objective on the stock. Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research note on Monday, February 24th. They issued an "outperform" rating and a $58.00 target price for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of Tourmaline Bio in a report on Wednesday, December 11th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $52.86.
Read Our Latest Stock Report on TRML
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Before you consider Tourmaline Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.
While Tourmaline Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.